abstract |
Provided herein are Apical Sodium-dependent Bile Acid Transporter Inhibitors (ASBTIs) for use in the treatment of diabetes in a diabetic individual. The ASBTIs provided herein are non-systemically absorbed ASBTIs that reaches the ileum, colon, and/or rectum of the individual with less than 10% systemic absorption. |